Table 2.
CMR and Cardiac MRS Findings
| Control Subjects (n = 12) |
Lean T2D Patients (n = 15) |
Obese T2D Patients (n = 27) |
p Value | |
|---|---|---|---|---|
| LV end-diastolic volume, ml | 145 ± 40 | 124 ± 33 | 126 ± 25 | 0.15 |
| LV ejection fraction, % | 68 ± 5 | 73 ± 7 | 68 ± 8 | 0.11 |
| LV mass, g | 91 ± 30 | 123 ± 33∗ | 119 ± 28∗ | 0.01 |
| LV mass index, g/m2 | 48 ± 11 | 66 ± 15∗ | 57 ± 10 | 0.001 |
| LV mass to LV end-diastolic volume, g/ml | 0.63 ± 0.13 | 0.95 ± 0.26∗ | 0.90 ± 0.20∗ | <0.001 |
| Peak systolic circumferential strain, negative (−), % | 18.1 ± 2.1 | 16.5 ± 2.6 | 13.4 ± 3.6† | <0.001 |
| Peak circumferential diastolic strain rate, s−1 | 74 ± 20 | 68 ± 19 | 56 ± 26† | 0.006 |
| Myocardial PCr/ATP ratio | 2.08 ± 0.40 | 1.75 ± 0.29∗ | 1.64 ± 0.32∗ | 0.003 |
| Myocardial triglyceride, % (lipid/water ratio) | 0.48 ± 0.28 | 1.14 ± 0.66∗ | 1.22 ± 0.91∗ | 0.004 |
Values are mean ± SD.
CMR = cardiac magnetic resonance; LV = left ventricular; MRS = magnetic resonance spectroscopy; PCr/ATP = phosphocreatine to adenosine triphosphate concentration ratio; T2D = type 2 diabetes.
∗
p < 0.05 versus control subjects with Bonferroni correction.
†
p < 0.05 versus lean patients with T2D and control subjects with Bonferroni correction.